After a long wait, two arrive, one after the other!

Thorax

Cystic fibrosis (CF) airways disease is unique, with chronic infection causing a localised but intense inflammatory process, acute in nature, but lasting for years.1 Prevention, eradication and suppression of airway infection have been the cornerstones of CF management, and success with these strategies has been a key factor in improving the outlook for people with CF.2 An armamentarium is available to achieve this goal, including a variety of aerosolised therapies. The evidence base to support these therapies ranges from good to poor.3 4 Individual patients respond uniquely, with therapeutic strategies working for some but not for others. It is complicated, and a team approach (including the patient) is essential to deliver the best regimen for each individual. What we do know with some certainty is that an aerosolised therapy does not work if it stays in the box or at the...